Related Experiment Video
Updated: Dec 27, 2025

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Triphenylphosphonium-modified mitochondria-targeted paclitaxel nanocrystals for overcoming multidrug resistance
Xue Han1, Ruijuan Su1, Xiuqing Huang1
1Shenyang Pharmaceutical University, Shenyang 110016, China.
Abstract:
Mitochondria are currently known as novel targets for treating cancer, especially for tumors displaying multidrug resistance (MDR). This present study aimed to develop a mitochondria-targeted delivery system by using triphenylphosphonium cation (TPP+)-conjugated Brij 98 as the functional stabilizer to modify paclitaxel (PTX) nanocrystals (NCs) against drug-resistant cancer cells. Evaluations were performed on 2D monolayer and 3D multicellular spheroids (MCs) of MCF-7 cells and MCF-7/ADR cells. In comparison with free PTX and the non-targeted PTX NCs, the targeted PTX NCs showed the strongest cytotoxicity against both 2D MCF-7 and MCF-7/ADR cells, which was correlated with decreased mitochondrial membrane potential. The targeted PTX NCs exhibited deeper penetration on MCF-7 MCs and more significant growth inhibition on both MCF-7 and MCF-7/ADR MCs. The proposed strategy indicated that the TPP+-modified NCs represent a potentially viable approach for targeted chemotherapeutic molecules to mitochondria. This strategy might provide promising therapeutic outcomes to overcome MDR.
Insights
This study developed mitochondria-targeted paclitaxel nanocrystals (PTX NCs) using TPP+-conjugated Brij 98 to combat multidrug resistance (MDR) in cancer. The targeted PTX NCs demonstrated superior efficacy against drug-resistant cancer cells and spheroids.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Therapy
Background:
- Mitochondria are emerging targets for cancer treatment, particularly in multidrug-resistant (MDR) tumors.
- Developing effective drug delivery systems is crucial for overcoming MDR.
Purpose of the Study:
- To create a mitochondria-targeted paclitaxel (PTX) delivery system using triphenylphosphonium cation (TPP+)-conjugated Brij 98.
- To evaluate the efficacy of TPP+-modified PTX nanocrystals (NCs) against drug-resistant cancer cells.
Main Methods:
- Functionalization of PTX NCs with TPP+-conjugated Brij 98 for enhanced mitochondrial targeting.
- Assessment of cytotoxicity and cellular uptake in 2D monolayer and 3D multicellular spheroids (MCs) of MCF-7 and MCF-7/ADR cells.
- Evaluation of mitochondrial membrane potential and penetration depth in MCs.
Main Results:
- Targeted PTX NCs exhibited significantly higher cytotoxicity against both sensitive (MCF-7) and MDR (MCF-7/ADR) cells compared to free PTX and non-targeted NCs.
- The enhanced efficacy correlated with a reduced mitochondrial membrane potential.
- Targeted PTX NCs demonstrated improved penetration into 3D MCs and greater growth inhibition.
Conclusions:
- TPP+-modified PTX NCs represent a promising strategy for targeted delivery of chemotherapeutics to mitochondria.
- This approach shows potential for overcoming multidrug resistance in cancer therapy.
- The TPP+-conjugated Brij 98 stabilizer offers a viable method for creating mitochondria-targeted nanocarriers.
Related Concept Videos
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

